Key result
Electrophysiologic-guided therapy with Class IA antiarrhythmic drugs resulted in no deaths or sustained ventricular arrhythmias among 23 treated patients over a mean follow-up of 9.1 years.
Why the study?
Does EP-guided therapy with Class IA antiarrhythmic drugs prevent death or sustained ventricular arrhythmias in patients with idiopathic VF?
Population
34 consecutive patients with idiopathic ventricular fibrillation with or without Brugada syndrome.
Design
Cohort
Follow-up
mean 9.1 +/- 5.6 years
Authors
Loading...
May support EP-guided quinidine in idiopathic VF; hypothesis-generating and requires randomized confirmation.
Cohort (n=34)
Does EP-guided therapy with Class IA antiarrhythmic drugs prevent death or sustained ventricular arrhythmias in patients with idiopathic VF?
EP-guided therapy with Class IA antiarrhythmic drugs (mainly quinidine) appears highly effective for long-term prevention of arrhythmias and death in patients with idiopathic VF.
Belhassen et al. (1999) conducted a cohort in Idiopathic ventricular fibrillation with or without Brugada syndrome (n=34). Electrophysiologic-guided therapy with Class IA antiarrhythmic drugs (mainly quinidine) was evaluated on Death or sustained ventricular arrhythmia. Electrophysiologic-guided therapy with Class IA antiarrhythmic drugs resulted in no deaths or sustained ventricular arrhythmias among 23 treated patients over a mean follow-up of 9.1 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: